Loading...
Concerns about drug and food interactions and the ease of use of newer antidepressants have so decreased the popularity of monoamine oxidase inhibitors (MAOIs) that psychiatrists can complete residency without ever using them. This study, completed almost 10 years ago, examined the effectiveness of the prototypical MAOI phenelzine, alone or combined with group cognitive-behavioral therapy (GCBT), in treating 128 patients with social anxiety disorder meeting DSM-IV criteria.
In the acute phase, patients were randomized to phenelzine (mean, 66 mg/day), weekly GCBT, phenelzine in a similar dose (mean, 62 mg/day) combined with GCBT, or pill placebo for 12 weeks. Combined treatment and phenelzine alone (but not GCBT alone) produced significantly …